116,260 Shares in Aquestive Therapeutics, Inc. $AQST Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the second quarter, Holdings Channel.com reports. The firm purchased 116,260 shares of the company’s stock, valued at approximately $484,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Aquestive Therapeutics by 30.8% in the third quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after purchasing an additional 1,333,627 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Aquestive Therapeutics by 159.4% during the fourth quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock worth $13,132,000 after acquiring an additional 1,249,044 shares during the period. Bank of America Corp DE increased its holdings in Aquestive Therapeutics by 99.2% during the first quarter. Bank of America Corp DE now owns 2,405,050 shares of the company’s stock worth $9,981,000 after buying an additional 1,197,459 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Aquestive Therapeutics by 6,233.4% during the 4th quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock valued at $7,569,000 after buying an additional 1,153,175 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Aquestive Therapeutics by 804.6% during the 4th quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock valued at $7,678,000 after buying an additional 1,057,145 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on AQST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Wall Street Zen lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Oppenheimer started coverage on shares of Aquestive Therapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $8.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $8.50.

Aquestive Therapeutics Price Performance

AQST stock opened at $4.66 on Friday. Aquestive Therapeutics, Inc. has a one year low of $2.93 and a one year high of $7.55. The stock has a market cap of $584.88 million, a PE ratio of -7.17 and a beta of 1.49. The firm has a 50 day simple moving average of $4.18 and a two-hundred day simple moving average of $4.12.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. On average, research analysts expect that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of Aquestive Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the sale, the director owned 25,000 shares of the company’s stock, valued at $125,500. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by insiders.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.